Cat. No. 3025
Alternative Name: Seratrodast
Chemical Name: 7-(3,5,6-Trimethyl-1,4-benzoquinon-
Biological ActivityThromboxane A2 (TP) receptor antagonist. Antiasthmatic agent; inhibits platelet aggregation and bronchoconstriction induced by a TXA2 mimetic in guinea pigs.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Cui et al (2007) Leukotrienes and cyclooxygenase products mediate anaphylactic venoconstriction in ovalbumin sensitized rat livers. Eur.J.Pharmacol. 576 99. PMID: 17706964.
Kurokawa et al (1994) Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414. Biol.Pharm.Bull. 17 383. PMID: 8019502.
Ashida et al (1989) A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins 38 91. PMID: 2748922.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AA 2414 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AA 2414, supplier, Thromboxane, A2, TP, receptors, antagonists, TXA2, Prostanoid, prostaglandins, prostacyclins, eicosanoids, AA2414, Tocris Bioscience, Prostanoid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
November 12 - 16, 2016
San Diego, CA, USA